Loading
Imunon, Inc. Stock: price and insider trades · United States
US·Mcap US$5.9M
No insider purchase over the last 90 days. The latest was filed 28 Jan 2025.
Imunon, Inc.: what insiders have been doing
Every trade that managers of Imunon, Inc. disclose to SEC (Form 4) is tracked on this page. From 18 October 2025 to 18 October 2026, the disclosure feed for Imunon, Inc. logged 46 filings by 8 insiders.
The flow runs one way only: 6 sales worth €15k, from 1 insider, and no purchase. The amount is not disclosed for 1 filing. One trade stands out by size: a sale of €3,448 from Eylward Susan, disclosed on 4 August 2026, or 0.052% of market capitalisation.
The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 46 filings here. The full history, which starts in 2016, counts 11 purchases against 6 sales.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
75
Thresholds
n/a
Buy Volume
€132,021
11 ops. · all time
Sell Volume
€15,162
6 ops. · all time
Who traded when
BuySaleSusan Eylward6 sales
Since the insiders bought
- -71.8%Entry US$11.74 · Close at T+365 US$3.31
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.06
Analyst consensus
5 analysts1.25/5
US$10.00Target US$17.00(+1504%)US$25.00
Income statement
RevenueUS$430.5k
EBITDA-US$14M-3241% margin
Net income-US$14.5M0.0% margin
Valuation
PER (forward)-0.6x
P/Book2.6x
Beta2.01
Balance sheet & cash
Market capUS$5.9M
Total debtUS$1M
Free Cash Flow-US$14.2M
Debt / Equity187%
Profitability & ownership
ROE-429.7%
ROA-78.0%
% insiders6.1%
% institutions5.7%
Last declaration on 13 October 2026
Declarations75 total
1,249 shares@ US$1.080.022% mcap3.5% of flowCommon StockSEC:0001437749-26-032560:0
7,800 shares@ US$1.080.14% mcap8.2% of flowCommon StockSEC:0001437749-26-032563:0
2,977 shares@ US$1.080.053% mcap3.7% of flowCommon StockSEC:0001437749-26-032562:0
6,697 shares@ US$1.410.12% mcap11.0% of flowCommon StockSEC:0001437749-26-031362:0
4,390 shares@ US$1.410.078% mcap16.5% of flowCommon StockSEC:0001437749-26-031360:0
7,169 shares@ US$1.410.13% mcap10.6% of flowCommon StockSEC:0001437749-26-031363:0
4,211 shares@ US$1.470.080% mcap19.4% of flowCommon StockSEC:0001437749-26-030413:0
5,824 shares@ US$1.470.11% mcap9.9% of flowCommon StockSEC:0001437749-26-030415:0
5,504 shares@ US$1.470.10% mcap10.4% of flowCommon StockSEC:0001437749-26-030414:0
2,525 shares@ US$1.600.052% mcap11.3% of flowCommon StockSEC:0001437749-26-029405:0
2,525 shares@ US$1.56430.051% mcap11.1% of flowCommon StockSEC:0001437749-26-029405:1
3,626 shares@ US$1.600.075% mcap18.1% of flowCommon StockSEC:0001437749-26-029407:0
6,822 shares@ US$1.600.14% mcap14.0% of flowCommon StockSEC:0001437749-26-029408:0
7,371 shares@ US$1.600.15% mcap13.5% of flowCommon StockSEC:0001437749-26-029409:0
3,516 shares@ US$1.650.076% mcap18.3% of flowCommon StockSEC:0001437749-26-028186:0
2,449 shares@ US$1.650.053% mcap11.4% of flowCommon StockSEC:0001437749-26-028184:0
2,449 shares@ US$1.63030.052% mcap11.3% of flowCommon StockSEC:0001437749-26-028184:1
7,147 shares@ US$1.650.15% mcap13.7% of flowCommon StockSEC:0001437749-26-028185:0
6,615 shares@ US$1.650.14% mcap14.1% of flowCommon StockSEC:0001437749-26-028187:0
6,934 shares@ US$1.590.14% mcap16.8% of flowCommon StockSEC:0001437749-26-025667:0
2,541 shares@ US$1.56510.052% mcap11.3% of flowCommon StockSEC:0001437749-26-025661:1
3,649 shares@ US$1.590.076% mcap18.3% of flowCommon StockSEC:0001437749-26-025658:0
6,934 shares@ US$1.590.14% mcap17.7% of flowCommon StockSEC:0001437749-26-025665:0
5,010 shares@ US$1.590.10% mcap10.3% of flowCommon StockSEC:0001437749-26-025655:0
6,358 shares@ US$1.590.13% mcap11.8% of flowCommon StockSEC:0001437749-26-025660:0
25 of 75 declarations
About Imunon, Inc.
Imunon, Inc. is a company focused on developing immunotherapy treatments. It aims to provide innovative solutions for serious diseases.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
